Immunotherapy

Watch this free webinar to learn about the biggest opportunities for the future of cancer immunotherapy.   In this free webinar, you will hear from immunologist Dr Frédéric Triebel, CSO and CMO of Immutep, two experts from DeciBio: Dr Carl Schoellhammer, Principal, and Dr Joe Daccache, Senior Life Science Expert, Veronique Baron, Scientific Applications Manager, Marketing […]

This article is sponsored by Taconic. The cancer therapeutic landscape changed dramatically with the introduction of immune checkpoint inhibitors (ICIs) that target T cells and leverage a patient’s immune system. Success in targeting T cells as immunotherapy has prompted investigators to explore whether other immune cell types can be leveraged to develop efficacious oncology treatments. […]

The AACR Annual Meeting’s second clinical trials plenary session, ‘Hope for Rare Cancers: Novel Targeted and Immunotherapy Agents’, highlighted promising studies that suggest new treatment approaches for rare cancers. First Hippo-YAP pathway inhibitor shows success in advanced solid tumours Timothy A Yap reported on a study that provides the first clinical proof-of-concept for effectively drugging […]

Patients with relapsed or refractory multiple myeloma who were treated with the two highest doses of REGN5459, a bispecific antibody targeting BCMA and CD3, experienced a 90.5% overall response rate. This is according to results of a Phase I/II clinical trial presented at the AACR Annual Meeting 2023 in Florida. REGN5459 binds to BCMA on […]

John Maher, Leucid Bio, tells Megan Thomas about his work and offers valuable advice to others in this field. MT: Where do you work, and can you tell us what you’re working on at the moment? JM: I am Chief Scientific Officer of a CAR T-cell spin-out company called Leucid Bio. I am also a Clinician Scientist […]

DDW has published the latest addition to its Guide Series, ‘Find out about the global breakthroughs, opportunities and developments in cancer research.’ It is sponsored by IRBM. In this free, exclusive guide, you will learn more about: Where the global breakthroughs, opportunities and developments are in cancer research Why cancer-associated proteins could be the Achilles’ […]

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  As March draws to a close, this week’s key announcements have demonstrated the breadth of international approaches to tackling cancer, with vaccines, proenzymes, immunotherapies and […]

News round-up for 27-31 March by DDW Digital Content Editor Diana Spencer.   As March draws to a close, this week’s key announcements have demonstrated the breadth of international approaches to tackling cancer, with vaccines, proenzymes, immunotherapies and antibody-based treatments all currently under investigation around the world.  The top stories:  Drug discovery partners from UK and Japan target macrophages  […]

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  This week we have seen a number of developments in the treatment of solid tumours hitting the headlines. Pennsylvania researchers may have found […]

News round-up for 20-24 March by DDW Digital Content Editor Diana Spencer.  This week we have seen a number of developments in the treatment of solid tumours hitting the headlines. Pennsylvania researchers may have found a way to boost CAR-T therapy in these tumours, previously only successful in blood cancers, which could have huge implications for […]

Immutep, a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, has initiated AIPAC-003 (Active Immunotherapy, Eftilagimod Alpha, and Paclitaxel), an integrated Phase II/III trial to evaluate eftilagimod alpha (efti) in combination with paclitaxel for the treatment of metastatic HER2-neg/low breast cancer (MBC).   Regulatory approval has been received in the US […]

Diana Spencer explores the different ways the drug discovery sector is tackling colorectal cancer. Colorectal cancer is preventable with screening and often treatable when caught early, yet due to late diagnosis and chemotherapy resistance, it remains the second deadliest cancer in the United States. Held in the US March every year, the aim of National […]

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  As well as providing extensive coverage of the SLAS2023 meeting in San Diego and Rare Disease Day, DDW has also reported on a number of developments […]

News round-up for 27 February – 3 March by DDW Digital Content Editor Diana Spencer.  As well as providing extensive coverage of the SLAS2023 meeting in San Diego and Rare Disease Day, DDW has also reported on a number of developments in cancer drug discovery this week. Most notably, a 20-year mystery regarding the ‘dark matter’ of the […]

CAR-T cell therapy is effective in mice with ovarian cancer, according to a study published in The Journal for ImmunoTherapy of Cancer.   The study authors, who work at Karolinska Institutet, hope that the discovery will pave the way for a clinical trial to see how effective the treatment is for women with the disease.   “This […]

DDW’s Diana Spencer reports on the recent Avacta Therapeutics Science Day, which explored the latest exciting developments in precision and targeted treatments for cancer and asked what advances the future might bring. The Avacta Therapeutics Science Day brought together senior company scientists and international oncology experts to provide an overview of the current development of […]